最新临床证明:
间充质干细胞治疗2型及1型糖尿病均安全有效
结论
间充质干细胞治疗糖尿病的初步临床结果表明:静脉输注MSCs,具有安全性,没有观察到严重不良反应。MSCs可以降低糖尿病患者的HbA1c水平,减少患者每日胰岛素用量;部分糖尿病患者,实现了胰岛素独立,在3-12月不使用胰岛素;长期随访提示,MSCs可能对T2DM患者胰岛β细胞有保护作用,间充质干细胞可能是治疗T2DM患者的有效选择。
展望:干细胞助力逆转糖尿病自然病程
参考文献
1. IDF Diabetes Atlas 10th Edition. http://www.diabetesatlas.org/
2. Brown C, McKee C, Bakshi S, et al. Mesenchymal stem cells: Cell therapy and regeneration potential. J Tissue Eng Regen Med, 2019, 13(9):1738-1755.
3. Li Zang, et al. Efficacy and safety of umbilical cord‑derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single‑center, double‑blinded, randomized, placebo‑controlled phase II trial. Stem Cell Res Ther. 2022, 13 (1):180.
4. Jing Lu, et al. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study. Stem Cell Res Ther. 2021, 12(1):340.
5. Jianxia Hu,et al. Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes. Exp Ther Med. 2016, 12(3):1857-1866.